PrognomiQ
PrognomiQ raises $34M Series D at $180M valuation
Quick Facts
PrognomiQ: Series D Funding Round
PrognomiQ has successfully raised $34M in Series D funding, reaching a valuation of $180M.
Company Overview
Healthcare company developing multi-cancer early detection tests
Funding Details
The Series D round was led by Seer, with participation from Casdin Capital.
Company Information
- Headquarters: San Mateo, CA
- Founded: 2019
- Employees: 80+
- Category: HealthTech
Investment
PrognomiQ plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Seer: Verified investor in Series D
- Casdin Capital: Verified investor in Series D
Key Investors
About the Author
Related Company Reports
Abridge Raises $150M Series C to Transform HealthTech
Abridge has secured $150M Series C in funding to accelerate growth and innovation in the healthtech sector. Medical AI scribe platform automatically documenting patient-provider conversations and generating clinical notes...
Innovaccer Raises $275M Series F to Transform HealthTech
Innovaccer has secured $275M Series F in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform unifying patient data and providing analytics for value-based care and population health manage...
Truveta Raises $95M Series B to Transform HealthTech
Truveta has secured $95M Series B in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform aggregating de-identified patient records to accelerate medical research and drug development...
